SPY003 was well tolerated and exhibited an ~85-day half-life, supporting potential quarterly or twice annual maintenance ...

Teva Pharmaceutical Industries Ltd (TEVA) reports its 11th consecutive quarter of growth, driven by innovative products, ...

Q3 2025 Earnings Call Transcript November 4, 2025 Rigel Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $1 ...